Syros Pharmaceuticals, Inc. (0LC7.L)

5,48 +0,13 (+2,43%) Alla chiusura: 02:59PM BST

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340
https://www.syros.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 68

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Richard A. Young Ph.D.	Scientific Founder, Member of Scientific Advisory Board & Director	108,37k	N/D	1954
Dr. David A. Roth M.D.	Chief Medical Officer	679,52k	N/D	1963
Mr. Conley Chee	CEO, President & Director	N/D	N/D	1970
Dr. James E. Bradner M.D.	Founder	N/D	N/D	1972
Dr. Nathanael S. Gray Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Mr. Jason Haas	Chief Financial Officer	457,22k	N/D	1968
Ms. Karen Hunady M.S.	Director of Corporate Communications & Investor Relations	N/D	N/D	N/D
Mr. Gerald E. Quirk Esq., J.D.	Chief Legal Officer & Head of Business Development	127,07k	N/D	1968
Ms. Lisa Roberts	Vice President of Human Resources	N/D	N/D	N/D
Ms. Kristin Stephens	Chief Development Officer	N/D	N/D	1973

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Syros Pharmaceuticals, Inc. al 29 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.